Eosinophilic Esophagitis (EoE)
4
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
3100%
+ 2 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
RegeneronTARRYTOWN, NY
2 programs1
1
DupilumabPhase 3Monoclonal Antibody
dupilumabN/AMonoclonal Antibody
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
TakedaBudesonide oral suspension
One BiosciencesSolrikitug Low Dose
Sanofidupilumab
Clinical Trials (3)
Total enrollment: 483 patients across 3 trials
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
Start: Oct 2017Est. completion: Apr 2022133 patients
Phase 3Terminated
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Start: Oct 2024Est. completion: Aug 2027
Phase 2Active Not Recruiting
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Start: Nov 2024Est. completion: May 2030350 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 483 patients
Monoclonal Antibody is the dominant modality (100% of programs)
4 companies competing in this space